Association of retinol binding protein 4 and transthyretin with triglyceride levels and insulin resistance in rural thais with high type 2 diabetes risk
Tóm tắt
Retinol binding protein 4 (RBP4), a protein secreted by adipocytes and bound in plasma to transthyretin (TTR), has been associated with obesity, the early phase of insulin resistance, metabolic syndrome, and type 2 diabetes mellitus. The objective of this study was to elucidate the relationship between RBP4, TTR, triglyceride (TG) and type 2 diabetes risk in rural Thailand. We measured the serum RBP4, TTR, glucose, triglyceride and insulin levels, and glucose tolerance of 167 volunteers from Sung Noen District, Nakhon Ratchasima Province, Thailand. Student’s t-test, Pearson’s correlation and logistic regression analysis were used to evaluate the relationships between RBP4, TTR and type 2 diabetes markers. RBP4 and TTR levels, as well as homeostatic model assessment of insulin resistance (HOMA-IR) values, were significantly elevated among subjects with high triglyceride levels (p < 0.01, p < 0.05, p < 0.05, respectively). Triglyceride levels correlated with RBP4 (r = 0.34, p < 0.001) and TTR (r = 0.26, p < 0.01) levels, as well as HOMA-IR values (r = 0.16, p < 0.05). After adjustment for age and gender, the risk of hypertriglyceridemia was 3.7 times greater (95% CI =1.42–9.73, p = 0.008) in the highest RBP4 tertile as compared to the lowest tertile. Similarly, the highest TTR and HOMA-IR tertiles had greater risk of hypertriglyceridemia at 3.5 (95% CI = 1.30–9.20, p = 0.01) and 3.6 (95% CI = 1.33–9.58, p = 0.01) times higher than the respective lowest tertiles. The correlation between TTR and blood glucose was statistically significant (r = 0.18, p < 0.05), but not found this relationship in RBP4. The associations of RBP4 and TTR with hypertriglyceridemia and insulin resistance may have important implications for the risk of heart disease and stroke.
Tài liệu tham khảo
Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. New Engl J Med. 2006;354:2552–63.
Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care. 2006;29:2457–61.
Chavez AO, Coletta DK, Kamath S, Cromack DT, Monroy A, Folli F, et al. Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans. Am J Physiol Endocrinol Metab. 2009;296:E758–64.
Xu M, Li XY, Wang JG, Wang XJ, Huang Y, Cheng Q, et al. Retinol-binding protein 4 is associated with impaired glucose regulation and microalbuminuria in a Chinese population. Diabetologia. 2009;52:1511–9.
Murata M, Saito T, Otani T, Sasaki M, Ikoma A, Toyoshima H, et al. An increase in serum retinol-binding protein 4 in the type 2 diabetic subjects with nephropathy. Endocr J. 2009;56:287–94.
Li F, Xia K, Sheikh MS, Cheng J, Li C, Yang T. Retinol binding protein 4 promotes hyperinsulinism induced proliferation of rat aortic smooth muscle cells. Mol Med Rep. 2014;9:1634–40.
von Eynatten M, Lepper PM, Liu D, Lang K, Baumann M, Nawroth PP, et al. Retinol-binding protein 4 is associated with components of the metabolic syndrome, but not with insulin resistance, in men with type 2 diabetes or coronary artery disease. Diabetologia. 2007;50:1930–7.
Kowalska I, Straczkowski M, Adamska A, Nikolajuk A, Karczewska-Kupczewska M, Otziomek E, et al. Serum retinol binding protein 4 is related to insulin resistance and nonoxidative glucose metabolism in lean and obese women with normal glucose tolerance. J Clin Endocrinol Metab. 2008;93:2786–9.
Lewis JG, Shand BI, Frampton CM, Elder PA, Scott RS. Plasma retinol-binding protein is not a marker of insulin resistance in overweight subjects: a three year longitudinal study. Clin Biochem. 2008;41:1034–8.
Gavi S, Qurashi S, Stuart LM, Lau R, Melendez MM, Mynarcik DC, et al. Influence of age on the association of retinol-binding protein 4 with metabolic syndrome. Obesity (Silver Spring). 2008;16:893–5.
Zanotti G, Berni R. Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. Vitam Horm. 2004;69:271–95.
Pandey GK, Balasubramanyam J, Balakumar M, Deepa M, Anjana RM, Abhijit S, et al. Altered circulating levels of retinol binding protein 4 and transthyretin in relation to insulin resistance, obesity, and glucose intolerance in Asian Indians. Endocr Pract. 2015;21:861–9.
Patel A, Barzi F, Jamrozik K, Lam TH, Ueshima H, Whitlock G, et al. Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region. Circulation. 2004;110:2678–86.
Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation. 2007;115:450–8.
Murad MH, Hazem A, Coto-Yglesias F, Dzyubak S, Gupta S, Bancos I, et al. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord. 2012;12:2.
Henry N. Ginsberg. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:453–8.
Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol. 1998;81:18B–25B.
International Diabetes Federation. Diabetes atlas, 7th edition. 2017. www.idf.org/diabetesatlas. Accessed 21 June 2017.
International Diabetes Federation. WP Region. 2017. https://www.idf.org/our-network/regions-members/western-pacific/members/115-thailand.html. Accessed 21 June 2017.
World Health Organization. Cardiovascular disease. 2017. http://www.who.int/cardiovascular_diseases/en/. Accessed 21 June 2017.
World Health Organization. Noncommunicable Diseases (NCD) Country Profiles. 2014. http://www.who.int/nmh/countries/tha_en.pdf. Accessed 21 June 2017.
National Institutes of Health. Metabolic Syndrome. 2017. https://www.nhlbi.nih.gov/health/health-topics/topics/ms. Accessed 21 June 2017.
Raila J, Henze A, Spranger J, Mohlig M, Pfeiffer AFH, Schweigert FJ. Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in type 2 diabetic patients. Kidney Int. 2007;72:505–11.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143–421.
Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83(9B):25F–9F.
Steiner G. Hyperinsulinaemia and hypertriglyceridaemia. J Intern Med Suppl. 1994;736:23–6.
Despres JP. The insulin resistance-dyslipidemic syndrome of visceral obesity: effect on patients’ risk. Obes Res. 1998;6:8S–17S.
Bjorntorp P. New concepts in the relationship obesity--non-insulin dependent diabetes mellitus. Eur J Med. 1992;1:37–42.
Saki F, Ashkani-Esfahani S, Karamizadeh Z. Investigation of the relationship between retinol binding protein 4, metabolic syndrome and insulin resistance in Iranian obese 5-17 year old children. Iran J Pediatr. 2013;23:396–402.
Yoshida A, Matsutani Y, Fukuchi Y, Saito K, Naito M. Analysis of the factors contributing to serum retinol binding protein and transthyretin levels in Japanese adults. J Atheroscler Thromb. 2006;13:209–15.
Qi Q, Yu Z, Ye X, Zhao F, Huang P, Hu FB, et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab. 2007;92:4827–34.
Mostafaie N, Sebesta C, Zehetmayer S, Jungwirth S, Huber KR, Hinterberger M, et al. Circulating retinol-binding protein 4 and metabolic syndrome in the elderly. Wien Med Wochenschr. 2011;161:505–10.
Comucci EB, Vasques AC, Geloneze B, Calixto AR, Pareja JC, Tambascia MA. Serum levels of retinol binding protein 4 in women with different levels of adiposity and glucose tolerance. Arq Bras Endocrinol Metabol. 2014;58:709–14.
Ingenbleek Y, Young V. Transthyretin (prealbumin) in health and disease: nutritional implications. Annu Rev Nutr. 1994;14:495–533.
Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Retinol binding protein-4 levels and clinical features of type 2 diabetes patients. J Clin Endocrinol Metab. 2007;92:2712–9.
Cabré A, Lázaro I, Girona J, Manzanares JM, Marimón F, Plana N, et al. The APOA5-1131 T>C variant enhances the association between RBP4 and hypertriglyceridemia in diabetes. Nutr Metab Cardiovasc Dis. 2010;20:243–8.
West KM, Ahuja MM, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, et al. The role of circulating glucose and triglyceride concentrations and their interactions with other “risk factors” as determinants of arterial disease in nine diabetic population samples from the WHO multinational study. Diabetes Care. 1983;6:361–9.
Fontbonne A, Eschwège E, Cambien F, Richard JL, Ducimetière P, Thibult N, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris prospective study. Diabetologia. 1989;32:300–4.